+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Analysis Report 2025- Product Image
Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Analysis Report 2025- Product Image
New

Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102646
Description Jump to:
Undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma, is a rare and aggressive subtype of soft tissue sarcomas, accounting for approximately 1% of all malignancies. It has an incidence rate of 0.08 to 1 per 100,000 individuals. Despite advances in cancer treatment, there remains a significant unmet clinical need for effective therapies for undifferentiated pleomorphic sarcoma. Current treatment options, including surgery, radiation, and chemotherapy, often fall short of preventing recurrence or managing metastasis. The increasing focus on targeted therapies and innovative approaches is expected to drive pipeline growth, offering hope for improved outcomes in this challenging malignancy.

Report Coverage

The Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline Insight Report by the publisher gives comprehensive insights into undifferentiated pleomorphic sarcoma (UPS) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Undifferentiated Pleomorphic Sarcoma (UPS). The undifferentiated pleomorphic sarcoma (UPS) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The undifferentiated pleomorphic sarcoma (UPS) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with undifferentiated pleomorphic sarcoma (UPS) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to undifferentiated pleomorphic sarcoma (UPS).

Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline Outlook

Undifferentiated pleomorphic sarcoma (UPS) is a rare and aggressive form of soft tissue cancer, characterized by undifferentiated, abnormal cells with no identifiable origin. It commonly arises in deep tissues such as muscles or connective tissues, often linked to genetic mutations or radiation exposure. Typically presenting as a rapidly growing, painless lump, its symptoms vary depending on the tumor’s location and size.

Undifferentiated Pleomorphic Sarcoma (UPS) treatment prioritizes surgical removal of the tumor, complemented by radiation therapy to minimize recurrence risks. Chemotherapy, often with doxorubicin and ifosfamide, is utilized for advanced or metastatic cases. Innovative treatments, such as immunotherapy and targeted therapies, offer hope for resistant or recurrent tumors. Multidisciplinary strategies are essential for comprehensive care and improved outcomes.

Undifferentiated Pleomorphic Sarcoma (UPS) Epidemiology

Undifferentiated pleomorphic sarcoma (UPS) accounts for approximately 1% of all malignancies, with an incidence of 3 per 100,000 people. In the United States about 1,200 new cases are diagnosed annually, making it the most common type of soft tissue sarcoma, representing 14% of cases. Undifferentiated pleomorphic sarcoma predominantly affects individuals over 60 years old, with a higher prevalence in older populations.

Undifferentiated Pleomorphic Sarcoma (UPS) - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of undifferentiated pleomorphic sarcoma (UPS) drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total undifferentiated pleomorphic sarcoma (UPS) clinical trials.

Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the undifferentiated pleomorphic sarcoma (UPS) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for undifferentiated pleomorphic sarcoma (UPS).

Undifferentiated Pleomorphic Sarcoma (UPS) Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the undifferentiated pleomorphic sarcoma (UPS) report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in undifferentiated pleomorphic sarcoma (UPS) clinical trials:
  • Tracon Pharmaceuticals Inc.
  • BioAtla, Inc.
  • HRYZ Biotech Co.
  • Merck Sharp & Dohme LLC

Undifferentiated Pleomorphic Sarcoma (UPS) - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Undifferentiated Pleomorphic Sarcoma (UPS). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of undifferentiated pleomorphic sarcoma (UPS) drug candidates.

Doxorubicin

The National Cancer Institute (NCI) sponsored this Phase III trial to assess whether adding pembrolizumab to doxorubicin improves progression-free survival in undifferentiated pleomorphic sarcoma (UPS). This study involves 180 participants and is expected to conclude by June 30, 2026.

MASCT-I Combination with Doxorubicin and Ifosfamide

HRYZ Biotech Co. is sponsoring a Phase II study evaluating MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment of advanced soft tissue sarcoma, including undifferentiated pleomorphic sarcoma. The study aims to assess safety and efficacy, with completion expected by February 2027. The trial includes 148 participants and emphasizes innovative approaches for metastatic or unresectable sarcoma management.

Reasons To Buy This Report

The Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for undifferentiated pleomorphic sarcoma (UPS). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within undifferentiated pleomorphic sarcoma (UPS) pipeline insights.

Key Questions Answered in the Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight Report

  • What is the current landscape of undifferentiated pleomorphic sarcoma (UPS) pipeline drugs?
  • How many companies are developing undifferentiated pleomorphic sarcoma (UPS) drugs?
  • How many phase III and phase IV drugs are currently present in undifferentiated pleomorphic sarcoma (UPS) pipeline drugs?
  • Which companies/institutions are leading the undifferentiated pleomorphic sarcoma (UPS) drug development?
  • What is the efficacy and safety profile of undifferentiated pleomorphic sarcoma (UPS) pipeline drugs?
  • What are the opportunities and challenges present in the undifferentiated pleomorphic sarcoma (UPS) drug pipeline landscape?
  • Which company is conducting major trials for undifferentiated pleomorphic sarcoma (UPS) drugs?
  • What geographies are covered for undifferentiated pleomorphic sarcoma (UPS) clinical trials?
  • What are emerging trends in undifferentiated pleomorphic sarcoma (UPS) clinical trials?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Undifferentiated Pleomorphic Sarcoma (UPS)
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Undifferentiated Pleomorphic Sarcoma (UPS)
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Undifferentiated Pleomorphic Sarcoma (UPS): Epidemiology Snapshot
5.1 Undifferentiated Pleomorphic Sarcoma (UPS) Incidence by Key Markets
5.2 Undifferentiated Pleomorphic Sarcoma (UPS) - Patients Seeking Treatment in Key Markets
6 Undifferentiated Pleomorphic Sarcoma (UPS): Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Undifferentiated Pleomorphic Sarcoma (UPS): Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Undifferentiated Pleomorphic Sarcoma (UPS), Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Doxorubicin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Biological: Pembrolizumab
10.2.3 Other Drugs
11 Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Biological: Nivolumab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Doxorubicin, Ifosfamide, Eribulin, Pembrolizumab, Propranolol, Association of pembrolizumab + cabozantinib
11.2.3 Other Drugs
12 Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Palbociclib, Pembrolizumab
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drugs: DCC-3014, Avelumab, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
12.2.3 Biological: Nanoplexed Poly I:C BO-112
12.2.4 Other Drugs
13 Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Undifferentiated Pleomorphic Sarcoma (UPS), Key Drug Pipeline Companies
14.1 Tracon Pharmaceuticals Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 BioAtla, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 HRYZ Biotech Co.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Merck Sharp & Dohme LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Reports

Undifferentiated Pleomorphic Sarcoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Undifferentiated Pleomorphic Sarcoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2025 - Product Image

Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Soft Tissue Neoplasms Drug Pipeline Analysis Report 2025 - Product Image

Soft Tissue Neoplasms Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Liposarcoma Pipeline Analysis Report 2025 - Product Image

Liposarcoma Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Malignant Fibrous Histiocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Malignant Fibrous Histiocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 133 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.